Singapore markets open in 6 hours 14 minutes

Clene Inc. (CLNN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4009-0.0135 (-3.26%)
As of 02:46PM EDT. Market open.

Clene Inc.

6550 South Millrock Drive
Suite G50
Salt Lake City, UT 84121
United States
801 676 9695
https://clene.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees82

Key executives

NameTitlePayExercisedYear born
Mr. Robert Etherington MBACEO, President & Director1.06MN/A1967
Mr. Morgan R. Brown CPA, M.B.A.Chief Financial Officer584.88kN/A1968
Mr. Mark G. Mortenson ESQ.Chief Science Officer729.92kN/A1958
Mr. Jerry Miraglia J.D.General Counsel & Corporate SecretaryN/AN/AN/A
Mr. Michael T. HotchkinChief Development OfficerN/AN/AN/A
Ms. Mary Anne McneilHead of Human ResourcesN/AN/AN/A
Dr. Benjamin M. Greenberg M.D., M.H.S.Head of MedicalN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Corporate governance

Clene Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.